CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Retained Earnings (Deficit)	Accumulated Other Comprehensive Loss	Total
Beginning Balance, Amount at Dec. 31, 2014	$ 0	$ 38	$ 129,473	$ (5,431)	$ (40,488)	$ 0	$ 83,592
Beginning Balance, Shares at Dec. 31, 2014	0	3,835
Net proceeds from issuance of restricted stock, Amount	$ 0	$ 0	0	(117)	0	0	(117)
Net proceeds from issuance of restricted stock, Shares	0	5
Compensation expense on share-based awards	$ 0	$ 0	5,944	0	0	0	5,944
Conversion of 8.0% convertible notes, Amount	$ 0	$ 18	60,154	0	0	0	60,172
Conversion of 8.0% convertible notes, Shares	0	1,805
Issuance of stock for inducment, Amount	$ 0	$ 2	19,498	0	0	0	19,500
Issuance of stock for inducment, Shares	0	233
Stock issued in connection with the purchase of Zohydro ER, Amount	$ 0	$ 2	11,924	0	0	0	11,926
Stock issued in connection with the purchase of Zohydro ER, Shares	0	168
Net proceeds from sale of shares, Amount	$ 0	$ 1	394	0	0	0	395
Net proceeds from sale of shares, Shares	0	65
Net loss	$ 0	$ 0	0	0	(148,315)	0	(148,315)
Ending Balance, Amount at Dec. 31, 2015	$ 0	$ 61	227,387	(5,548)	(188,803)	0	33,097
Ending Balance, Shares at Dec. 31, 2015	0	6,111
Net proceeds from issuance of restricted stock, Amount	$ 0	$ 0	0	(23)	0	0	(23)
Net proceeds from issuance of restricted stock, Shares	0	4
Reclassification of treasury stock	$ 0	$ 0	(5,571)	5,571	0	0	0
Compensation expense on share-based awards	0	0	2,718	0	0	0	2,718
Net proceeds from sale of shares, Amount	$ 0	$ 39	19,775	0	0	0	19,814
Net proceeds from sale of shares, Shares	0	3,901
Net loss	$ 0	$ 0	0	0	(169,590)	0	(169,590)
Other comprehensine loss	0	0	0	0	0	(79)	(79)
Ending Balance, Amount at Dec. 31, 2016	$ 0	$ 100	$ 244,309	$ 0	$ (358,393)	$ (79)	$ (114,063)
Ending Balance, Shares at Dec. 31, 2016	0	10,016